

Intrabodies targeting the Kaposi sarcoma–associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells

Sofia Corte-Real, Chris Collins, Frederico Aires da Silva, J. Pedro Simas, Carlos F. Barbas III, Yuan Chang, Patrick Moore, and Joao Goncalves

Kaposi sarcoma–associated herpesvirus (KSHV) latency-associated nuclear antigen-1 (LANA1) is essential for the maintenance and segregation of viral episomes in KSHV latently infected B cells. We report development of intracellular, rabbit-derived antibodies generated by phage display technology, which bind to N-terminal LANA1 epitopes and neutralize the chromosome-binding activity of LANA1. Although these cloned single-chain variable fragments (scFvs) show

relatively low binding affinities for the LANA1 viral antigen in in vitro assays, they nonetheless outcompete KSHV-seropositive human sera for LANA1 epitope binding. In heterologous cells, intracellular intrabody expression inhibits LANA1-dependent plasmid maintenance of both an artificial plasmid containing KSHV LANA1 binding sequences and a bacterial artificial chromosome containing the entire KSHV genome. In KSHV naturally infected primary effusion lymphoma cells,

intracellular intrabody expression causes a reduction or loss of the typical LANA1 punctate, nuclear pattern. This morphologically apparent LANA1 dispersion correlates to loss of viral episome by molecular analysis. These data suggest a novel approach to antiherpes viral therapy and confirm LANA1 is critical target for neutralization of KSHV viral latency. (Blood. 2005;106:3797-3802)

© 2005 by The American Society of Hematology

Introduction

Kaposi sarcoma–associated herpesvirus (KSHV or human herpesvirus 8 [HHV-8]) is a double-stranded DNA gammaherpesvirus associated with KS, primary effusion lymphoma (PEL), and subsets of multicentric Castlemann disease (MCD), an aggressive lymphoproliferative disorder.¹⁻³ KSHV predominantly infects B lymphocytes and endothelial cells and persists as a closed, circular episome expressing few viral genes during latent replication.⁴ While KS rates among AIDS patients have dramatically decreased with the use of highly effective antiretroviral therapy,⁵ therapeutic options for MCD or PEL are limited, and these neoplastic diseases have high mortality rates.^{1,6,7} Persistent, latent KSHV infection is not amenable to common antiviral drugs targeting the lytic-phase herpesvirus-encoded DNA polymerase.⁸

One latent protein, the latency-associated nuclear antigen-1 (LANA1) encoded by open reading frame 73 (ORF73),^{9,10} is consistently expressed in all forms of KS-associated malignancies.¹¹⁻¹⁴ LANA1 tethers the viral episome to cellular chromosomes during mitosis, allowing equal segregation of virus genome to daughter cells.^{12,14-17} LANA1 is a large nuclear protein with an N-terminal proline-rich domain, an internal glutamine-rich domain, and an acidic repeat domain followed by a leucine zipper motif.^{18,19} LANA1 binds through a C-terminal region to 2 adjacent sites within each KSHV terminal repeat (TR), which acts as the latent origin of replication for the viral episome.^{20,21} LANA1 N-terminal amino acids 5 to 22 form a chromosome binding sequence (CBS) that

interacts with chromatin proteins and is sufficient to mediate a specific interaction of LANA1 with chromosomes during mitosis.^{16,22,23} A second region in the C-terminus (from amino acids 1129 to 1143) has been described as essential for heterochromatin association but is not sufficient alone to mediate this interaction.^{24,25} Thus, by binding the episome through its C-terminal domain and chromosome-associated proteins through its N-terminal domain, LANA1 acts as a physical bridge between the episome and cellular chromosomes during mitosis. In vitro assays for KSHV plasmid maintenance in heterologous cell types have been developed in which LANA1 expression is used to maintain an artificial plasmid with antibiotic selection markers containing the TR replication origins.¹² In addition to its episome maintenance functions, LANA1 inhibits retinoblastoma protein (pRB1),²⁶ p53,²⁷ and glycogen synthase kinase-3 β (GSK-3 β)²⁸ and is likely to contribute to KSHV-related tumorigenesis. It is, in many respects, functionally analogous to the well-studied large T antigen of simian virus 40 (SV40).

Because of LANA1's central role in maintaining KSHV, it is an attractive target for therapeutics designed to eliminate latent KSHV infection. Unfortunately, siRNA against LANA1 mRNA fails to inhibit KSHV replication,²⁹ presumably due to the stability of LANA1 protein (J. Wieszorek, R. Sarid, Y. Chang, unpublished observation), which ensures that sufficient protein is available for viral replication under these conditions.

From the URIA-Centro de Patogénese Molecular, Faculty of Pharmacy, University of Lisbon, Portugal; Molecular Virology Program, Hillman Cancer Research Center, University of Pittsburgh, PA; Department of Molecular Biology and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA; and Laboratório de Microbiologia e Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Portugal; and Instituto Gulbenkian de Ciência, Oeiras, Portugal.

Submitted April 21, 2005; accepted July 28, 2005. Prepublished online as *Blood* First Edition Paper, August 9, 2005; DOI 10.1182/blood-2005-04-1627.

Supported by grants from the Fundação para a Ciência e Tecnologia, Portugal (POCTI/33096/MGI/2000 and PSIDA/MGI/49729/2003) and the National

Institutes of Health/National Cancer Institute. S.C.-R and F.A.S. are recipients of a doctoral fellowship from Fundação para a Ciência e Tecnologia, Portugal.

Reprints: Joao Goncalves, URIA-Centro de Patogénese Molecular, Faculty of Pharmacy, University of Lisbon, 1649-019 Lisbon, Portugal; e-mail: joao.goncalves@ff.ul.pt; or Patrick Moore, Yuan Chang—Molecular Virology Program, Hillman Cancer Research Center, University of Pittsburgh, Pittsburgh, PA 15213-1863; e-mail: psm9+@pitt.edu; yc70@pitt.edu.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2005 by The American Society of Hematology

We have taken an alternative approach to neutralize LANA1 function through intrabody expression. Intrabodies (antibodies for intracellular applications) are single-chain variable region antibody fragments that can be expressed through transfection or by using a viral vector.^{30,31} The potential of intrabodies to neutralize the function of intracellular and extracellular proteins has been demonstrated in several applications.^{32,34} In this study, we generated 2 anti-LANA1 intrabodies by phage display technology specific for the N-terminal CBS domain, which efficiently inhibits KSHV maintenance in PEL cells. We show that loss of KSHV episome in these cells results in cell death without the induction of viral lytic reactivation. These findings suggest a novel therapeutic approach to inhibit KSHV latent viral replication.

Materials and methods

Expression and purification of LANA1 proteins

LANA1 was amplified by polymerase chain reaction (PCR) from pSG5 LANA1-FLAG¹² (a kind gift from Dr Kenneth Kaye, Harvard University, Cambridge, MA) into 2 separate fragments, LANA₁₀₀₀ (amino acids 1 to 337) and LANA₂₀₀₀ (amino acids 337 to 1162), due to the existence of a repeat region (region rich in proline and glycine) between 1000 bp and 2000 bp that complicated both amplification and purification of such a large protein. A polyhistidine tag (His₆) was added at the N-terminal end of each fragment. Primers used were as follows: LANA₁₀₀₀: (sense [S]) 5'-ATGGCGCCCCGGGA-ATGC-3' and (antisense [AS]) 5'-CTAATGGTGATGGTGATGCTGCTC-CTCATCTGTCTCTCTGC-3'; LANA₂₀₀₀: (S) 5'-ATGCAGGAGACAGATGAGGAGACGAGGAGG-3' and (AS) 5'-CTAATGGTGATGGTGATGCTCATTTCCTGTGGAGAGTCCCCAGGTGG-3'. These products were cloned into pBad-TOPO (Invitrogen, Carlsbad, CA) and expressed in bacteria by induction with arabinose. LANA₁₀₀₀ was purified by fast protein liquid chromatography (FPLC)-affinity chromatography using nickel-nitrilotriacetic acid (Ni-NTA) resin; and LANA₂₀₀₀ was purified by ionic exchange chromatography followed by molecular exclusion chromatography.

Phage display library

Two New Zealand white rabbits were immunized with purified LANA₁₀₀₀ and LANA₂₀₀₀ proteins. Spleens and bone marrows were harvested separately³⁵ for total RNA using TRI Reagent (Molecular Research Center, Cincinnati, OH). First-strand cDNA was synthesized using Superscript (Invitrogen). Rabbit V_L and V_H sequences were combined with human C_L and C_{H1} sequences by overlap PCR, as previously described.³⁴ PCR fragments encoding a library of antibody fragments (Fabs) were digested with *Sfi*I, purified, and cloned into pComb3X,³⁵ which contains an amber stop codon, His₆ tag for purification, and hemagglutinin (HA) for detection.³⁵ Fab fragments were expressed in fusion with protein III of M13 phage and screened against LANA1 proteins. A total of 88 anti-LANA1 Fabs were expressed, purified, and screened by enzyme-linked immunosorbent assay (ELISA) against LANA₁₀₀₀ and LANA₂₀₀₀ proteins. For the conversion of a LANA1-specific Fab into a single-chain variable domain fragment (scFv), specific oligonucleotide primers covering all known rabbit antibody family sequences were used to amplify V_H and V_L gene segments.³⁵ The purified PCR products were assembled by overlapping PCR, and the resulting PCR products encoded different scFvs in which the V_L region was linked with the V_H region through an 18-amino acid peptide linker (SSGGGGSGGGGGSSRSS). DNA fragments were gel purified, digested with *Sfi*I, and cloned into pComb3X. LANA1 binding activity of the corresponding scFv was confirmed, and the genes encoding the scFv were cloned into pCDNA3.1/Zeo (+) (Invitrogen).³⁵ ScFv proteins were purified using BD TALON Metal Affinity columns (Clontech, Palo Alto, CA) as previously described.³³ Purified scFv proteins were analyzed by immunoblotting using standard methods. 4BL is an irrelevant scFv used as control.³³

Mapping LANA1 epitopes

LANA1 epitopes were mapped using 171 cleavable, biotinylated (N-terminus SGSK) 17-mer peptides offset by 5 amino acids as previously described.³⁶ Briefly, streptavidin ELISA plates (Roche Applied Science, Indianapolis, IN) were coated with 1.5 µg of each peptide. After blocking with 3% bovine serum albumin/phosphate-buffered saline (BSA/PBS), peptides 5 to 73 (amino acids 1 to 357) were incubated with purified scFv BM9 and BM10. Detection was performed by horseradish peroxidase (HRP)-conjugated anti-HA monoclonal antibody (high affinity 3F10; Roche Applied Science) at a dilution of 1:3000. Absorbance was measured on a spectrophotometer (Biophotometer; Eppendorf, Hamburg, Germany) at 405 nm.

Competition assay

Streptavidin ELISA plates (Roche Applied Science) coated overnight at 4°C with 1.8 µg of each peptide were blocked, washed, and then incubated for 2 hours at 37°C with sera that had been preincubated for 30 minutes with the different scFvs (0.1 µg). After blocking, unbound proteins were removed with wash buffer containing Tween 20, and an HRP-conjugated anti-HA monoclonal antibody (high affinity 3F10; Roche Applied Science) was added at a dilution of 1:3000 for 1 hour at 37°C. HRP activity was detected by 2,2'-azino-bis(3-ethylthiazolidine-6)-sulfonic acid (ABTS), and absorbance was measured on a spectrophotometer (Biophotometer; Eppendorf) at 405 nm.

Cell lines and transfection procedures

CM12 cells from a poorly defined but highly transfectable human epithelial cell line were cultured in Dulbecco modified Eagle medium (DMEM) (GibcoBRL, Carlsbad, CA) with 10% fetal calf serum (FCS) (GibcoBRL), 0.05 µg/mL penicillin/streptomycin, and 2 mM L-glutamine. BJAB cell lines stably transfected with KSHV Z6 and containing 8 copies of TR (FL-9/8TR), flag-tagged LANA1 (FL-9), and empty vector (pSG5) were kindly provided by Dr Kenneth Kaye.¹² BC-1 (American Type Culture Collection [ATCC], Manassas, VA), BCBL1 (AIDS Research and Reference Reagent Program, Bethesda, MD), and BJAB were cultured in RPMI 1640 supplemented with 10% FCS, 1 mM sodium pyruvate, and 2 mM L-glutamine. All cell cultures were maintained at 37°C in 5% CO₂. CM12 cells were transfected with KSHV-bacterial artificial chromosome-36 (KSHV-BAC36) plasmid (kind gift from S. J. Gao, San Antonio Cancer Institute, TX) either transiently or stably using Fugene 6 (Roche Applied Science) according to the manufacturer's instructions. Selection for stable KSHV-BAC36 was performed in 150 µg/mL hygromycin. BJAB (solution R, program T-01) and PEL cells (solution V, program T-01) were transfected (5 µg DNA and 1 × 10⁶ cells per transfection) using Amaxa nucleofection (Amaxa, Cologne, Germany). Transfection efficiency measured by fluorescence-activated cell sorter (FACS) analysis was 47% for BC-1 cells and 57.1% for BCBL-1 cells.

Immunofluorescence staining and antibodies

BJAB and KSHV-infected cells were placed on glass slides using a cytospin (Shandon, Pittsburgh, PA). Cells were fixed in 4% paraformaldehyde and permeabilized in 1% Triton X-100/PBS. Cells were incubated with the primary antibodies for LANA1 (CMA-810; 1:500 dilution) or His₆ (Roche Applied Science; 1:1000 dilution) for 1 hour at room temperature in a humidified chamber, washed with 0.1% Tween 20/PBS, and incubated with species-appropriate fluorescein isothiocyanate (FITC)- (1:500 dilution) or rhodamine isothiocyanate (RITC)- (1:1000 dilution) conjugated secondary antibodies for 1 hour at room temperature. Slides were mounted with DAPI (4,6 diamidino-2-phenylindole) Vectashield (Vector Labs, Burlingame, CA) to stain nuclei, and cells were visualized using an Olympus AX70 epifluorescence microscope (Olympus, Melville, NY) with triple color filters, and a 20 × air objective. Numerical aperture varied automatically according to the light emitted. Images were captured with a Zeiss Axiocam camera (Zeiss, Göttingen, Germany). Cells were arrested in metaphase with 0.1 µg/mL colcemid (Irvine Scientific, Santa Ana, CA) for 24 hours and resuspended in 0.075 M KCl for 12 minutes to swell nuclei. Immunofluorescence assay (IFA) was performed as described.

Outgrowth assays

For selection of pSG5-LANA1 48 hours after transfection FL-9/8TR and FL-9 cell cultures were grown in medium containing 200 U/mL hygromycin (Invitrogen) to select for LANA1. For selection of Z6 cosmid, cell cultures were grown in medium containing 400 μ g/mL neomycin (G418) (Invitrogen), and for selection of pcDNA3.1 Zeo (+)-derived constructs, cell cultures were grown in medium containing 200 μ g/mL zeocin (Invitrogen) to select for scFv. Cell viability was determined using the cell proliferation reagent WST-1 (Roche Applied Science) according to the manufacturer's instructions. The activity of mitochondrial dehydrogenases, an indicator of cell viability, was measured in 10 000 cells by the conversion of the tetrazolium salt WST-1 to the red dye formazan. Formazan accumulation is detected by increased absorbance at 440 nm.

Gardella gel analysis

Gardella experiments were performed as described elsewhere.³⁷ Briefly, cells were separated by Ficoll and resuspended in 15% Ficoll/0.01% bromophenol blue/TBE (Tris–borate–ethylenediaminetetraacetic acid) buffer, loaded onto a vertical 0.8% agarose gel, and overlaid with lysis buffer (5% Ficoll, 1% sodium dodecyl sulfate [SDS], 1 mg/mL pronase, and 0.05% xylene cyanol green) After electrophoresis, DNA was transferred to nitrocellulose membranes by Southern blotting and detected with KSHV-TR ³²P-labeled probes (Redi-Prime; Amersham Biosciences, Piscataway, NJ).

Transcription/translation in vitro and GST pulldown

In vitro transcription and translation (TNT System; Promega, San Luis Obispo, CA) of pCDNA3.1/scFv was performed according to the manufacturer's instructions. Radiolabeled scFv proteins were incubated overnight at 4°C with 3 μ g purified glutathione S-transferase (GST)–LANA1. Glutathione Sepharose beads (Amersham Biosciences) were washed with PBS/0.1% Nonidet P-40 (NP-40)/60 mM EDTA (ethylenediaminetetraacetic acid) together with antiproteases and added to labeled scFv/LANA1-GST mix, incubated at 4°C, and washed with PBS. Samples were analyzed by 12% SDS–polyacrylamide gel electrophoresis (PAGE) and subjected to autoradiography.

Results

Selection of LANA1-specific antibody fragments

A chimeric rabbit/human Fab library was generated from cDNA from bone marrow and spleen RNA from 2 immunized rabbits having a strong antibody response to a mixture of LANA1 protein fragments (amino acids 1 to 337 and 337 to 1162). An antibody library of 1×10^8 independent clones was constructed and selected. Several Fab clones binding LANA1 protein fragments were then isolated and converted to single-chain variable fragments (scFvs) by PCR. An 18–amino acid linker fragment (SSGGGGGSSSRSS) was cloned between the V_L and V_H fragments, connecting the C-terminal end of the V_L fragment to the N-terminal end of the V_H fragment. This linker allows the intrabody to be expressed from a single cloned cDNA and provides enhanced intracellular stability of the expressed antibody.³³ Figure 1A summarizes the relative binding for the Fab clones prior to scFv construction. From the selected clones, we used 2 Fabs, BM9 and BM10, with highest relative binding to convert into scFvs, for further characterization and expression.

scFv specificity for LANA1

To test specificity of constructed scFvs, cell extracts from BJAB cell lines stably transfected with LANA1 and Z6 cosmid (containing 8 copies of the KSHV-TR)¹² were separated by 6% SDS-PAGE and immunoblotted with purified anti-LANA1 scFvs




Figure 1. BM9 and BM10 scFvs bind to the N-terminal CBS domain of LANA1 with low but specific binding. (A) Representative enzyme-linked immunosorbent assay activities for 10 Fab clones isolated by phage display from LANA1-immunized rabbits. Clones BM9 and BM10 having highest immunoreactivity were subcloned into single-chain Fv (scFv) and examined for LANA1 binding. (B) HA epitope-tagged BM9, but not BM10, scFv binds LANA1 on direct immunoblotting. FL-9/8TR and FL-9 are BJAB cell lines constitutively expressing LANA-1 protein, and pSG5 is a BJAB cell line transfected with empty vector alone. (C) In vitro binding of BM9 scFv to a GST-LANA1 fusion protein. In this assay, [³⁵S]methionine-labeled BM9 scFv but not BM10 scFv directly interacted with GST-LANA1 fusion protein isolated with glutathione-linked beads. (D) Human serum competition assay: BM9 was mixed with the indicated dilutions of KSHV LANA1-seropositive human serum, and ELISAs were performed using plates coated with peptides P7, P8, P9, P19, and P43. BM9 competes with hyperimmune sera for peptide binding with P7, P8, and P43 but not with P19. Each point represents the value of binding minus nonspecific binding of scFv or human serum to uncoated wells blocked with 3% BSA/PBS. (E) Schematic representation of LANA1 and binding epitopes of BM9, BM10, and other cellular proteins that bind to its N-terminal domain.

(Figure 1B). BM9, but not BM10, recognized the major LANA1 doublet band of approximately 220 kDa in cell extracts from FL-9 and FL-9/8TR, BJAB cell lines constitutively expressing LANA1 protein. No bands were detected using a transfected cell line with empty control pSG5 vector. Similarly, immunoprecipitation of [³⁵S]methionine-labeled BM9 and BM10 with GST-LANA1 fusion protein demonstrated interaction between LANA1 and BM9 but not BM10 (Figure 1C). Despite this evidence for in vitro BM9 scFv binding to LANA1, direct immunoprecipitation of LANA1 using the specific monoclonal antibody CMA-810, followed by immunoblot detection with either BM9 or BM10, failed to detect direct interaction, suggesting a weak recognition of the epitope by the scFv. To map anti-LANA1 scFv epitopes, LANA1 peptide screening using 171 biotinylated peptides was performed by ELISA using the purified BM9 and BM10 scFvs, as previously described, to determine dominant epitopes recognized by sera from KSHV-infected patients.³⁶ BM9 and BM10

Table 1. Mapping of LANA1 epitopes using immunoreactive peptides 5-73 of KSHV LANA1 against BM9 and BM10

Peptide	Position	Amino acid sequence	BM9	BM10
P7	11-27	GRSTGAPLTRGSCRKRN	+	+
P8	16-32	APLTRGSCRKRNRSPER	+	+
P9	21-37	GSCRKRNRSPERCDLGD	-	+
P19	71-87	FTSGLPAFVSSPTLPVA	+	-
P43	191-207	LAPSTLRSLRKRRLSS	+	+

Scanning peptide ELISA shows that peptides including LANA1 amino acid residues 11 to 32 (peptides P7-P8) and 11 to 37 (P7-P9) are bound by BM9 and BM10, respectively; BM9 also showed reactivity to residues 71-87 (P19); and both scFvs reacted to residues 191 to 207 (P43).

(Table 1; Figure 1E) bound to peptides encompassing the N-terminal sequence motif (amino acids 5 to 22) containing the chromosome binding site involved in tethering LANA1 to cellular chromosomes during mitosis²² as well as to a putative nuclear localization signal (NLS) of LANA1 (amino acids 24 to 30).¹⁶ Both scFvs also bound to peptide 43, which has not been described as relevant to LANA1 CBS or NLS functions. To determine if BM9 reacts to epitopes also recognized during natural KSHV infection, we competed the scFv with KS-positive human serum for binding to specific LANA1 peptides. In this assay, biotinylated peptides bound to streptavidin plates were incubated with BM9 with or without KSHV-positive serum overnight. As seen in Figure 1D, increasing optical absorbance values at higher dilutions of human serum indicate that native anti-LANA1 human antibodies compete with LANA1-specific BM9 for peptides encompassing N-terminal protein motif. These results show that single-chain antibodies that can bind LANA1 protein at its N-terminal end are capable of competing with anti-LANA1 sera for the antigen. Thus, LANA1 protein is specifically recognized *in vitro* by BM9. Taken together, these data show weak but specific LANA1 interaction with BM9. Despite this apparent low binding, the effectiveness of intrabodies expressed *in vivo* is highly dependent on antibody stability, which allows relatively low-binding antibodies to successfully neutralize intracellular functions.³⁸ For this reason, neutralization of LANA1 function may be a more sensitive indicator of anti-LANA1 scFv specificity, and thus both BM9 and BM10 antibodies were examined in functional studies.

Functional analysis of intrabodies against LANA1

Functional studies were performed in cell lines stably transfected with LANA1 and Z6 (FL9/8TR) and in CM12 cells stably transfected with the KSHV-BAC36 clone.³⁹ In FL-9/8TR cells, a hygromycin resistance marker is encoded on the pSG5 LANA1 plasmid and a neomycin resistance marker on the Z6 cosmid. The TR-multimer plasmid (KSHV Z6 cosmid) is maintained through transexpression of LANA1 protein. Expression of BM9 and BM10 results in inhibition of LANA1 function and consequent loss of the TR plasmid. When either BM9 and/or BM10 are transfected into FL-9/8TR, susceptibility to neomycin cell killing occurs within 5 days of scFv expression, whereas cells transfected with empty vector (pcDNA 3.1) continue to replicate, reflecting the loss and maintenance of the TR plasmid, respectively (Figure 2A). Cells expressing either BM9 and/or BM10 have shown loss of TR plasmid by day 14 of culture compared with cells expressing an irrelevant anti-HIV scFv, 4BL (data not shown). These results were confirmed by cotransfection of the anti-LANA1 intrabodies with a cloned KSHV-BAC36 expressing enhanced green fluorescent protein (EGFP). When BM9 or BM10 are transfected together with




Figure 2. Expression of BM9 or BM10 inhibits KSHV plasmid maintenance in a FL-9 heterologous cell assay. Outgrowth assays of FL-9/8TR BJAB cells stably expressing LANA1 under a hygromycin resistance marker and together with a KSHV-TR plasmid under a neomycin resistance marker show that BM9 (●) and BM10 (zeocyn selection) (○), but not pcDNA3.1 vector (▲), induce inhibition of LANA1 and consequent loss of TR plasmid. Cells were transfected with the intrabodies or empty vector and placed under hygromycin, neomycin (LANA1-TR plasmid), and zeocyn (intrabody/vector) selection on day 0 (48 hours after transfection). Cell counts were performed in 24 replicas using the cell proliferation reagent WST-1 and measured by spectrophotometer at 405 nm.

KSHV-BAC36 DNA into CM12 cells, rapid loss of EGFP fluorescence occurs within 48 hours (Figure 3A) with corresponding loss of the episomal KSHV-BAC36 as shown by Gardella gel electrophoresis (Figure 3B).

Intrabody neutralization of LANA1 in PEL cells

To determine if anti-LANA1 intrabody expression in naturally infected PEL cells inhibits KSHV episome maintenance, BM9 and BM10 were transfected into BC-1 (infected with Epstein-Barr virus [EBV] and KSHV) and BCBL-1 cells (infected with KSHV alone). LANA1 knockdown by expression of anti-LANA1 scFvs BM9 and BM10 in both PEL cell lines show marked short-term growth inhibition when anti-LANA1 scFvs are expressed compared with the irrelevant control intrabody, 4BL, cloned in the same plasmid backbone (Figure 4A-B). This corresponds to dispersion of LANA1 protein expression as depicted by IFA (in red) when anti-LANA1-specific scFvs are expressed (in green) (Figure 4D), and confirmed by Western blot (Figure 4C). ScFv expression in BC-1 cells has a greater effect in inhibiting cell growth than in BCBL-1. This may indicate that KSHV is the essential oncogenic virus driving these tumors. As previously described, LANA1 has a punctate nuclear pattern in PEL cells due to the colocalization of LANA1 with KSHV episomes when attached to cellular chromosomes. Using cytogenetically prepared mitotic spreads of PEL cells arrested in metaphase with colchicine treatment, the number of LANA1-positive punctate signals averages 40 per cell. Expression of anti-LANA1 scFv disperses LANA1 and significantly reduces the number of LANA1 nuclear dots per mitotically arrested cell




Figure 3. BM9 or BM10 expression promotes loss of KSHV plasmid in CM12 during transient transfection. Gardella gel electrophoresis followed by Southern blot hybridization with a TR probe shows loss of viral genome from CM12 cells stably transfected with KSHV-BAC36 GFP and transiently transfected with BM9 and BM10. Transfection with the negative control 4BL intrabody has no effect on viral persistence.




Figure 4. Expression of BM9 and BM10 inhibits PEL cell growth and reduces endogenous expression of LANA1 protein. Short-term growth curves for BCBL-1 (A) and BC-1 (B) cells transfected with BM9 (●), BM10 (○), and 4BL (◆) scFvs and selected with zeocyn show growth inhibition with anti-LANA1 scFv expression contrary to 4BL, an irrelevant HIV-specific intrabody. (C) Immunoblotting for LANA1 in BCBL-1 cells transfected with BM9, BM10, and 4BL shows a diminished protein level when BM9 and BM10 are expressed compared with 4BL and untransfected control cells. (D) Distribution of LANA1 and anti-LANA1 scFvs in BC-1 cells with immunofluorescence microscopy after simultaneous detection with mLANA1 and monoclonal HA. LANA1's speckled pattern becomes dispersed when BM9 and BM10 are expressed. scFv is shown in green (FITC) and LANA1 in red (rhodamine). Magnification $\times 1000$.

(Figure 5; Table 2). When an irrelevant antibody is expressed, no apparent effect is observed in the number of LANA1 chromosomally associated dots. These results strongly correlate with the loss of the TR plasmid when coexpressed with BM9 and BM10, as described.

Discussion

Intracellular expression and antigen targeting using cloned scFvs represents a novel tool for dissecting biologic processes. Unlike technologies that target nucleic acids, intrabodies operate at the posttranslational level and can be directed to relevant subcellular compartments and precise epitopes on target proteins, potentially blocking only one of several possible functions of an expressed protein. Moreover, this technique holds advantages over other knockdown technologies, such as RNAi or ribozyme cleavage, for long-lived cellular proteins. In this study, we demonstrate that intrabodies neutralize the function of LANA1, which reduces viral persistence in infected cells.

Although antiviral drugs targeting the KSHV lytic replication can inhibit viremia, these agents do not eliminate persistent latent KSHV. During latency, most viral genes are silent, and




Figure 5. Nuclear dispersion of LANA1 by BM9 and BM10 expression. Quantitation of LANA1 speckles in metaphase spreads demonstrates diminished chromatin-associated LANA1 in cells expressing BM9 or BM10 compared with 4BL. Magnification $\times 1000$.

Table 2. Evaluating dispersion of LANA1 due to scFv expression in BC-1 cells

scFv	Total no. of cells counted	Mean no. of LANA1	P: scFv vs untransfected	P: scFv vs 4BL
BM9	10	9.5	< .001	< .001
BM10	13	18.54	< .001	< .001
4BL/control	3	41.67	.49	NA
Untransfected	7	38.44	NA	NA

LANA1 spots were counted and the Student *t* test effectuated to statistically compare between scFvs and controls. Student *t* tests *P* values for average differences, assuming equal variances and unpaired; 2-tailed for among controls or among treatment comparisons and 1-tailed for treatment versus controls.

NA indicates not applicable.

thus there are few viral proteins that can be targeted to eliminate latent viral infection. Unlike most other KSHV proteins, LANA1 expression appears to be required for virus-infected cells to maintain the viral episome and to silence cellular antiviral responses mediated through regulatory proteins such as p53. RNAi has been described as a means to inhibit KSHV latency and shows therapeutic promise.²⁹ RNAi against LANA1, however, is ineffective possibly due to the long half-life of this protein, allowing even small amounts of LANA1 message to code for sufficient protein to allow maintenance of the viral episome. Intrabody technology might therefore hold advantages in eliminating persistent KSHV infection by directly targeting the active viral protein.

In this study, we generated anti-LANA1 single-chain antibodies from immunized rabbits having weak binding to LANA1. Despite this, both BM9 and BM10 cause episome loss when expressed in KSHV-infected cells. This LANA1 neutralization is most likely to be related to N-terminal specificity for the intrabodies because this region is required for LANA1 interaction with cellular chromatin-associated proteins. LANA1 is a multifunctional viral protein that inhibits pRB1, p53, and GSK-3 β signaling.^{26-28,40-42} Although we have not formally examined whether BM9 and BM10 neutralization may also inhibit these or other cellular signaling pathways, our data show that at least a disruption of the mitotic bridge between cellular chromatin and the viral episome occurs. In either case, cellular growth of PEL cells expressing active antiLANA1 intrabodies is markedly reduced. Ongoing studies are being conducted to determine precisely how neutralization causes this effect.

The effectiveness of these relatively low-affinity scFvs in inhibiting latent KSHV infection provides a proof of principle for the feasibility of using engineered intracellular antibodies as a novel therapy against latent viral infections. Intrabody fragments could be delivered through gene therapy allowing direct treatment of latently infected cells. In situ lysis of latently infected cells may provoke a protective immune response against viral antigens that could extend the efficacy of this form of treatment. The development of high-affinity anti-LANA1 scFv antibodies might result in even more efficacious anti-KSHV agents.

Acknowledgments

We thank Sofia Coelho for technical assistance and Dr Kenneth Kaye (Harvard University) for the kind gift of reagents.

References

- Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castlemann's disease. *Blood*. 1995;86:1276-1280.
- Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. *N Engl J Med*. 1995;332:1186-1191.
- Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science*. 1994;266:1865-1869.
- Sarid R, Flore O, Bohenzky RA, Chang Y, Moore PS. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). *J Virol*. 1998;72:1005-1012.
- Jones JL, Hanson DL, Dworkin MS, Ward JW, Jaffe HW. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group. *J Acquir Immune Defic Syndr*. 1999;21(suppl 1):S11-S17.
- Ablashi DV, Chatlynne LG, Whitman JE Jr, Cesarman E. Spectrum of Kaposi's sarcoma-associated herpesvirus, or human herpesvirus 8, diseases. *Clin Microbiol Rev*. 2002;15:439-464.
- Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castlemann's disease, and pleural effusion lymphoma. *Lancet Infect Dis*. 2002;2:344-352.
- Moore PSM, Chang Y. Kaposi's sarcoma associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? *Annu Rev Microbiol*. 2003;57:609-639.
- Rainbow L, Platt GM, Simpson GR, et al. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. *J Virol*. 1997;71:5915-5921.
- Kedes DM, Operskalski E, Busch M, Kohn R, Flood J, Ganem D. The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. *Nat Med*. 1996;2:918-924.
- Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castlemann's disease, and primary effusion lymphoma. *Proc Natl Acad Sci U S A*. 1999;96:4546-4551.
- Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. *Science*. 1999;284:641-644.
- Szekely L, Kiss C, Mattsson K, et al. Human herpesvirus-8-encoded LNA-1 accumulates in heterochromatin-associated nuclear bodies. *J Gen Virol*. 1999;80(pt 11):2889-2900.
- Cotter MA II, Robertson ES. The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. *Virology*. 1999;264:254-264.
- Fejer G, Medveczky MM, Horvath E, Lane B, Chang Y, Medveczky PG. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts preferentially with the terminal repeats of the genome in vivo and this complex is sufficient for episomal DNA replication. *J Gen Virol*. 2003;84:1451-1462.
- Barbera AJ, Ballestas ME, Kaye KM. The Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 N terminus is essential for chromosome association, DNA replication, and episome persistence. *J Virol*. 2004;78:294-301.
- Hu J, Garber AC, Renne R. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells. *J Virol*. 2002;76:11677-11687.
- Russo JJ, Bohenzky RA, Chien MC, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). *Proc Natl Acad Sci U S A*. 1996;93:14862-14867.
- Neipel F, Albrecht JC, Fleckenstein B. Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? *J Virol*. 1997;71:4187-4192.
- Ballestas ME, Kaye KM. Kaposi's sarcoma associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA. *J Virol*. 2001;75:3250-3258.
- Garber AC, Hu J, Renne R. Latency-associated nuclear antigen (LANA) cooperatively binds to two sites within the terminal repeat, and both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication. *J Biol Chem*. 2002;277:27401-27411.
- Piolot T, Tramier M, Coppey M, Nicolas JC, Marechal V. Close but distinct regions of human herpesvirus 8 latency-associated nuclear antigen 1 are responsible for nuclear targeting and binding to human mitotic chromosomes. *J Virol*. 2001;75:3948-3959.
- Wong LY, Matchett GA, Wilson AC. Transcriptional activation by the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen is facilitated by an N-terminal chromatin-binding motif. *J Virol*. 2004;78:10074-10085.
- Viejo-Borbolla A, Kati E, Sheldon JA, et al. A domain in the C-terminal region of latency-associated nuclear antigen 1 of Kaposi's sarcoma-associated herpesvirus affects transcriptional activation and binding to nuclear heterochromatin. *J Virol*. 2003;77:7093-7100.
- Schwam DR, Luciano RL, Mahajan SS, Wong L, Wilson AC. Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies. *J Virol*. 2000;74:8532-8540.
- Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. *Nat Med*. 2000;6:1121-1127.
- Friborg J Jr, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. *Nature*. 1999;402:889-894.
- Krithivas A, Fujimuro M, Weidner M, Young DB, Hayward SD. Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes. *J Virol*. 2002;76:11596-11604.
- Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. *Blood*. 2005;105:2510-2518.
- Cattaneo A, Biocca S. *Intracellular Antibodies*. New York, NY: Springer-Verlag; 1997.
- Barbas CF, Burton DR. Selection and evolution of high-affinity human anti-viral antibodies. *Trends Biotechnol*. 1996;14:230-234.
- Marasco WA, ed. *Intrabodies: Basic Research and Clinical Gene Therapy Applications*. New York, NY: Springer-Verlag; 1998.
- Goncalves J, Silva F, Freitas-Vieira A, et al. Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication. *J Biol Chem*. 2002;277:32036-32045.
- Steinberger P, Sutton JK, Rader C, Elia M, Barbas CF III. Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. *J Biol Chem*. 2000;275:36073-36078.
- Barbas CF III, Burton R, Scott JK, Silverman GJ. *Phage Display: A Laboratory Manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001.
- Olsen SJ, Sarid R, Chang Y, Moore PS. Evaluation of the latency-associated nuclear antigen (ORF73) of Kaposi's sarcoma-associated herpesvirus by peptide mapping and bacterially expressed recombinant western blot assay. *J Infect Dis*. 2000;182:306-310.
- Gardella T, Medveczky P, Sairenji T, Mulder C. Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis. *J Virol*. 1984;50:248-254.
- Aires da Silva F, Santa-Marta M, Freitas-Vieira A, et al. Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity. *J Mol Biol*. 2004;340:525-542.
- Zhou FC, Zhang YJ, Deng JH, et al. Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. *J Virol*. 2002;76:6185-6196.
- Platt GM, Simpson GR, Mitnacht S, Schulz TF. Latent nuclear antigen of Kaposi's sarcoma-associated herpesvirus interacts with RING3, a homolog of the *Drosophila* female sterile homeotic (fsh) gene. *J Virol*. 1999;73:9789-9795.
- Lim C, Gwack Y, Hwang S, Kim S, Choe J. The transcriptional activity of cAMP response element-binding protein-binding protein is modulated by the latency associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. *J Biol Chem*. 2001;276:31016-31022.
- Lu F, Zhou J, Wiedmer A, Madden K, Yuan Y, Lieberman PM. Chromatin remodeling of the Kaposi's sarcoma-associated herpesvirus ORF50 promoter correlates with reactivation from latency. *J Virol*. 2003;77:11425-11435.



blood[®]

2005 106: 3797-3802

doi:10.1182/blood-2005-04-1627 originally published online
August 9, 2005

Intrabodies targeting the Kaposi sarcoma–associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells

Sofia Corte-Real, Chris Collins, Frederico Aires da Silva, J. Pedro Simas, Carlos F. Barbas III, Yuan Chang, Patrick Moore and Joao Goncalves

Updated information and services can be found at:

<http://www.bloodjournal.org/content/106/12/3797.full.html>

Articles on similar topics can be found in the following Blood collections

[Gene Therapy](#) (599 articles)

[Immunobiology and Immunotherapy](#) (5653 articles)

[Neoplasia](#) (4182 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:

<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://www.bloodjournal.org/site/subscriptions/index.xhtml>